19
Sep
2023
Turning the Tables: Rob Perez Interviews Me on The Long Run
This episode is unusual. Many listeners know of Rob Perez. He’s an operating partner at General Atlantic, the former CEO of Cubist Pharmaceuticals, and the founder of Life Science Cares. Rob and I have gotten to know each other better the past couple years through our shared passion for mobilizing the biotech community to fight poverty. The Timmerman Traverse for... Read More
6
Sep
2023
Freeing the Biotech Founders: Zach Weinberg and Alexis Borisy on The Long Run
Today there are two guests on The Long Run: Zach Weinberg and Alexis Borisy. They are co-founders of Curie.Bio. Curie is a venture capital fund with $520 million, mostly for seed investments and Series A rounds in biotech startups. It also is also building up in-house R&D expertise which it uses to help the entrepreneurs it backs. Curie pitches itself... Read More
5
Sep
2023
A Return to Kilimanjaro: Timmerman Traverse for Damon Runyon Cancer Research
Welcome to the next big biotech expedition — Timmerman Traverse for Damon Runyon Cancer Research Foundation. A team of executives, investors, and scientists are coming together on Kilimanjaro, the highest peak in Africa, in February 2024. We’re on a mission to raise $1 million for young scientists across the US. Damon Runyon gives promising young researchers the freedom to pursue... Read More
31
Aug
2023
Danaher Wins Over Abcam, Sage Cuts, & FTC Ceases Fire With Amgen
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2023
Rapport’s $150M Advance, Regeneron’s New COVID Challenge, and a Traverse for the Ages
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2023
How ‘Living Medicine’ Came to Be: Fred Appelbaum on The Long Run
Today’s guest is Fred Appelbaum. Fred is a physician, scientist, and administrator. He’s an executive vice president at the Fred Hutchinson Cancer Center in Seattle. He’s also the author of a new book, “Living Medicine: Don Thomas, Marrow Transplantation and the Cell Therapy Revolution” published by Mayo Clinic Press. It’s excellent. Fred knows a lot of this story from firsthand... Read More
17
Aug
2023
Gilead Bets on Multi-Functionals, Taysha Revived & Google Spotlights Illumina Rival
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Aug
2023
Sage Gets FDA OK for PPD, Wegovy’s Home Run, & Illumina’s Gloomy Quarter
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2023
Digging into Data, Finding New Drug Targets: Colin Hill on The Long Run
Today’s guest on The Long Run is Colin Hill. He’s the co-founder and CEO of Aitia (pronounced Ay-tee-ah). The company was founded in 2000, and previously known as GNS Healthcare. The GNS part was short for Gene Network Sciences, which gives you some sense of what it was about. Aitia is a new name to reflect a new strategy. The... Read More
8
Aug
2023
Recursion Screens Protein-Small Molecule Interactions at Vast Scale
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2023
Revolution Absorbs EQRX, Pfizer Itches to Close Seagen, & Boundless Preps for IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2023
Kyverna Tacks on $60M to Take CAR-T for Autoimmunity Further in the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jul
2023
Alnylam’s Big Roche Deal, Biogen Cuts 1,000 Jobs, & Pneumococcal Vaccine Competition
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jul
2023
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jul
2023
A-Alpha Bio Raises $22.4M to Further Build SynBio and AI Drug Discovery Platform
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2023
Betting on Bold and Brave Ideas for Cancer: Yung Lie on The Long Run
Today’s guest on The Long Run is Yung Lie. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation. The New York-based foundation supports some of the best young scientists around the US and gives them funds to pursue their bold and brave ideas. To give just one example, it bet on cancer immunotherapy research when it... Read More
20
Jul
2023
FTC Scrutinizes M&A, Tessier-Lavigne Steps Down, and BridgeBio’s Comeback
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jul
2023
Neumora Advances to Phase III with Depression Drug, Hires AbbVie Vet as CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jul
2023
Westlake Village Raises $450M for Biotech Startups in LA and Beyond
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jul
2023
Recursion’s Big Day, FDA OKs OTC Birth Control & a Midsummer IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.